[No abstract available]2262339340Bachmann, J.M., Willis, B.L., Ayers, C.R., Association between family history and coronary heart disease death across long-term follow-up in men: the Cooper Center Longitudinal Study (2012) Circulation, 125, pp. 3092-3098Sesso, H.D., Lee, I.M., Gaziano, J.M., Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women (2001) Circulation, 104, pp. 393-398Santos, R.D., Nasir, K., Insights into atherosclerosis from invasive and non-invasive imaging studies: should we treat subclinical atherosclerosis? (2009) Atherosclerosis, 205, pp. 349-356Sarwar, A., Shaw, L.J., Shapiro, M.D., Diagnostic and prognostic value of absence of coronary artery calcification (2009) JACC Cardiovasc Imaging, 2, pp. 675-688Nasir, K., Budoff, M.J., Wong, N.D., Family history of premature coronary heart disease and coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA) (2007) Circulation, 116, pp. 619-626Nasir, K., Michos, E.D., Rumberger, J.A., Coronary artery calcification and family history of premature coronary heart disease: sibling history is more strongly associated than parental history (2004) Circulation, 110, pp. 2150-2156Joshi, P.H., Xu, H., LeStrange, R., The M235T single nucleotide polymorphism in the angiotensinogen gene is associated with coronary artery calcium in patients with a family history of coronary artery disease (2013) Atherosclerosis, 226 (2), pp. 433-439Ashby, D.T., Rye, K.A., Clay, M.A., Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells (1998) Arterioscler Thromb Vasc Biol, 18, pp. 1450-1455Kontush, A., de Faria, E.C., Chantepie, S., Antioxidative activity of HDL particle subspecies is impaired in hyperalphalipoproteinemia: relevance of enzymatic and physicochemical properties (2004) Arterioscler Thromb Vasc Biol, 24, pp. 526-533de Beer, M.C., Durbin, D.M., Cai, L., Apolipoprotein A-I conformation markedly influences HDL interaction with scavenger receptor BI (2001) J Lipid Res, 42, pp. 309-313Yancey, P.G., de la Llera-Moya, M., Swarnakar, S., High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI (2000) J Biol Chem, 275, pp. 36596-36604Williams, P.T., Fifty-three year follow-up of coronary heart disease versus HDL2 and other lipoproteins in Gofman's Livermore Cohort (2012) J Lipid Res, 53, pp. 266-272Khera, A.V., Cuchel, M., de la Llera-Moya, M., Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis (2011) N Engl J Med, 364, pp. 127-135Bostrom, K., Watson, K.E., Horn, S., Bone morphogenetic protein expression in human atherosclerotic lesions (1993) J Clin Invest, 91, pp. 1800-1809Tsai, M.Y., Johnson, C., Kao, W.H., Cholesteryl ester transfer protein genetic polymorphisms, HDL cholesterol, and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis (2008) Atherosclerosis, 200, pp. 359-367Marenberg, M.E., Risch, N., Berkman, L.F., Genetic susceptibility to death from coronary heart disease in a study of twins (1994) N Engl J Med, 330, pp. 1041-1046Zdravkovic, S., Wienke, A., Pedersen, N.L., Heritability of death from coronary heart disease: a 36-year follow-up of 20 966 Swedish twins (2002) J Intern Med, 252, pp. 247-254Kretowski, A., McFann, K., Hokanson, J.E., Polymorphisms of the renin-angiotensin system genes predict progression of subclinical coronary atherosclerosis (2007) Diabetes, 56, pp. 863-871Armstrong, Z.B., Boughner, D.R., Drangova, M., Angiotensin II type 1 receptor blocker inhibits arterial calcification in a pre-clinical model (2011) Cardiovasc Res, 90, pp. 165-170Yano, H., Hibi, K., Nozawa, N., Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor (2012) Circ J, 76, pp. 1442-1451Yusuf, S., Sleight, P., Pogue, J., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators (2000) N Engl J Med, 342, pp. 145-153